Janjigian, Y. Y., Park, B. J., Zakowski, M. F., Ladanyi, M., Pao, W., D’Angelo, S. P., . . . Azzoli, C. G. (2011). Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.
Chicago Stili AlıntıJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.
MLA AlıntıJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.